Evaluating a blood test for early cancer detection in high-risk individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research evaluates the GRAIL Galleri multi-cancer early detection test, which is designed to identify various types of cancer through a blood sample. The study targets individuals at higher-than-average risk for developing cancer, including those with specific genetic predispositions or family histories of cancer. Participants will undergo eligibility screening, blood tests, and complete questionnaires over a period of up to three years, with an expected enrollment of around 1,000 individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria Group 1- Cancer Predisposition Syndrome:

* Age ≥ 22 for patients with TP53 germline pathogenic variants, age ≥ 35 for all other variants in cancer predisposing genes
* Germline genetic testing revealed pathogenic germline variants in cancer predisposing genes (list of genes typically tested listed in pre-screening document)
* Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)

Inclusion Criteria Group 2 - Familial Risk:

* Age ≥ 45
* Adults with family history suggestive of elevated cancer risk as defined by any the criteria below, who do not fall into Group 1:

  * ≥ 1 first or second degree relative on same side of the family with:

    * Breast, colon, gastric, endometrial, kidney cancer at or before age 50
    * Triple negative breast cancer (any age)
    * Male breast cancer (any age)
    * Ovarian, pancreatic, sarcoma cancer (any age)
    * Neuroendocrine cancer or tumors (any age)
    * Metastatic prostate cancer (any age)
    * Multiple primary cancers (example bilateral breast cancer)
  * ≥ 2 first or second degree relative on same side of the family (any combination is acceptable) with breast or prostate cancer at any age

Exclusion Criteria:

* Individuals diagnosed with invasive malignancy within 3 years of enrollment
* Have had a blood-based multi-cancer screening test within last year
* Individuals with evidence of symptomatic or active cancer requiring active therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is considered acceptable and will not preclude participation)
* Individuals in Group 2 whose family history of cancer was the result of a germline mutation in a cancer predisposing gene and who have tested negative for that same familial germline mutation
* Individuals in Group 2 whose family history of cancer is sex-specific and who is a different sex than the proband with cancer (e.g., a male with a family history of endometrial or ovarian cancer would not be eligible)
* Individuals in process of being evaluated for clinical suspicion of cancer
* Individuals who have undergone a cancer risk-reducing surgery for hereditary cancer risk (e.g., mastectomy)

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Elizabeth ODonnell, MD — Dana-Farber Cancer Institute
• Study coordinator: Elizabeth ODonnell, MD
• Email: dfciprevention@mgb.org
• Phone: 617-762-2334

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Collecting data to predict cancer risk in at-risk populations

  This study is trying to collect samples and health information from people at higher risk of cancer to see if they can find signs that help predict cancer early on.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05463796

• Transition outcomes for adolescents and young adults with a cancer predisposition.

  See if young adults with a genetic cancer predisposition establish and keep up care with adult providers and follow recommended cancer surveillance after they leave pediatric care at St. Jude.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07456904

• How genes and alcohol interact to affect liver cancer risk

  This project will test if certain gene variants together with alcohol use and metabolic problems raise the risk of liver cancer in people with fatty or cryptogenic liver disease, especially men with diabetes or obesity.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan, Milano · NCT07272200

• Topical 5% minoxidil to boost blood flow and skin‑flap survival during breast reconstruction

  This trial will test whether applying 5% topical minoxidil to one breast before bilateral risk‑reducing mastectomy with immediate reconstruction improves blood flow and skin‑flap survival compared with a placebo on the other breast.

  Recruiting Phase 1 Duke University · Durham, North Carolina · NCT07264790

• Slow-SPEED: Can a smartphone app help people with prodromal Parkinson's stay more active?

  This trial tests whether a remote smartphone app can help people with a LRRK2 G2019S or GBA1 N370S mutation increase daily activity and see if exercise might slow prodromal Parkinson's signs.

  Recruiting Radboud University Medical Center · Rochester, New York and 1 other locations · NCT06993142

• Understanding how genetics and lifestyle affect endometrial cancer recurrence

  This study is trying to see how genetics and lifestyle factors like obesity and diabetes affect the chances of endometrial cancer coming back in patients.

  Recruiting Faculty Hospital Kralovske Vinohrady · Prague · NCT06680791

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.